Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286149 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
A Phase 1 study of Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 3
- Study locations
NCT07286149 is a Phase 1 study of Lung Neoplasm Malignant that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 190 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT07286149, a Phase 1 study of Lung Neoplasm Malignant, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 3
- Study locations
Study Summary
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Cetuximab
- DRUG Rescue Medications
- BIOLOGICAL Patritumab deruxtecan
- DRUG MK-1084
Study Locations (3)
Other
- Shaare Zedek Medical Center ( Site 0186) - Jerusalem
- Severance Hospital, Yonsei University Health System ( Site 0080) - Seoul
Florida
- Clermont Oncology Center ( Site 0041) - Clermont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2037-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07286149
The ClinicalTrials.gov registry entry for NCT07286149 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Neoplasm Malignant appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT07286149 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07286149 about?
NCT07286149 is a clinical study titled "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)". Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK...
What is the current status of trial NCT07286149?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2026-03-23. Estimated completion is 2037-05-06.
What conditions does trial NCT07286149 study?
This clinical trial studies the following conditions: Lung Neoplasm Malignant.
What interventions are being tested in trial NCT07286149?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Cetuximab (BIOLOGICAL), Rescue Medications (DRUG), Patritumab deruxtecan (BIOLOGICAL), MK-1084 (DRUG).
Who is sponsoring clinical trial NCT07286149?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07286149 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasm Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.